4.7 Article

EZH2 Inhibitor Enhances the STING Agonist.Induced Antitumor Immunity in Melanoma

期刊

JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 142, 期 4, 页码 1158-+

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2021.08.437

关键词

-

资金

  1. National Natural Science Foundation of China [82073011, 81972562]
  2. Beijing Natural Science Foundation [7202024]
  3. Beijing Talents Foundation [2016000021223ZK18]

向作者/读者索取更多资源

This study reveals a previously unreported mechanism of epigenetic regulation of STING expression in melanoma and demonstrates that a combination of STING agonists and EZH2 inhibitors can enhance the antitumor immune response, offering a promising treatment option for melanoma patients refractory to current immunotherapies.
STING agonists are a new class of drugs for cancer immunotherapy that activate both innate and adaptive antitumor immunity. Recently, multiple clinical trials of STING agonists have been conducted in hematological malignancies and solid tumors. However, STING is commonly suppressed in melanoma through mechanisms that remain unclear. We found that STING expression was epigenetically suppressed by H3K27me3 in melanoma, and EZH2 inhibitor could induce an H3K27 shift from trimethylation to acetylation, resulting in increased expression of STING. Furthermore, a combination of STING agonist and EZH2 inhibitor upregulated major histocompatibility complex class I expression and chemokine production. Whole-transcriptome analysis showed that IFN-1.related genes were significantly upregulated in the combination treatment group. In addition, the combination treatment synergistically reduced tumor growth and increased CD8 thorn T-cell infiltration in a poorly immunogenic melanoma mouse model B16-F10. These results showed, to our knowledge, a previously unreported mechanism underlying the epigenetic regulation of STING expression in melanoma; a combination of STING agonists and EZH2 inhibitors can boost the antitumor immune response and would be a promising treatment option for patients with melanoma who are refractory to current immunotherapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据